Co-amoxiclav is Safe for Lactating Mothers
Co-amoxiclav (amoxicillin-clavulanic acid) is compatible with breastfeeding and can be safely used by nursing mothers. 1
Evidence from Guidelines
Multiple high-quality international guidelines consistently classify co-amoxiclav as "Compatible" with breastfeeding:
- The 2020 ERS/TSANZ Task Force Statement explicitly lists amoxicillin+clavulanic acid (B1) [FDA Category B] as "Compatible" for breastfeeding 1
- The 2025 Global IBD Consensus Statement confirms that "amoxicillin and vancomycin are also considered low risk in nursing mothers" 2
Drug Transfer and Infant Exposure
The FDA drug label states that "ampicillin-class antibiotics are excreted in the milk; therefore, caution should be exercised when amoxicillin and clavulanate potassium is administered to a nursing woman" 3. However, this cautious language reflects regulatory requirements rather than clinical risk.
Recent pharmacokinetic data demonstrates minimal infant exposure:
- Milk-to-plasma concentration ratios for amoxicillin range from only 4.5% to 9.6% 4
- The relative infant dose (RID) remains <0.4% regardless of maternal dosing regimen 4
- These extremely low transfer rates explain why no adverse effects have been reported in breastfed infants 4
Clinical Safety Data
A prospective study of 67 breastfeeding women taking amoxicillin-clavulanic acid found:
- 22.3% of infants experienced minor adverse effects (primarily loose stools or mild gastrointestinal symptoms) 5
- This rate was higher than amoxicillin alone (7.5%), likely due to the clavulanic acid component 5
- All adverse effects were self-limiting and did not require interruption of breastfeeding 5
- The rate of adverse effects increased with higher maternal doses 5
Practical Monitoring Recommendations
While co-amoxiclav is safe, monitor breastfed infants for:
- Diarrhea or loose stools (most common effect)
- Oral or perianal candidiasis (yeast overgrowth from altered gut flora)
- Falsely negative cultures if the infant develops fever requiring evaluation 1
These effects result from antibiotic presence in breast milk altering the infant's intestinal flora 1, but they are temporary and resolve after maternal treatment ends.
Important Caveats
One specific contraindication exists: The 2020 ERS/TSANZ guidelines note that amoxicillin+clavulanic acid is "not recommended in women at risk of pre-term delivery (very low risk of necrotising enterocolitis in the fetus)" 1. This refers to pregnancy use, not lactation, but highlights the need to consider timing if treating peripartum infections.
Comparison to Alternative Antibiotics
Co-amoxiclav compares favorably to other commonly used antibiotics during lactation:
- Safer than metronidazole, which the 2025 IBD consensus advises against during breastfeeding due to higher milk concentrations and unknown effects on infant microbiome 2
- Similar safety profile to cephalosporins like cefuroxime, which are also rated "Compatible" 1
- Preferable to fluoroquinolones like ciprofloxacin, which clinicians generally try to avoid during lactation despite low actual risk 1
Bottom Line
Breastfeeding should continue during maternal co-amoxiclav therapy. The combination is well-established as compatible with lactation across multiple authoritative guidelines. While minor gastrointestinal effects may occur in some infants, these are self-limited and do not warrant treatment discontinuation or cessation of breastfeeding. The benefits of continued breastfeeding far outweigh the minimal risks of antibiotic exposure through breast milk.